Mediators of Inflammation, 1, [151] [152] [153] [154] [155] [156] [157][158][159][160][161][162][163][164][165] (1992) 5-AMINOSALICYLIC ACID (5-ASA) has been used for over 50 years in the treatment of inflammatory bowel disease in the pro-drug form sulphasalazine (SASP). SASP is also used to treat rheumatoid arthritis. However whether the therapeutic properties of SASP are due to the intact molecule, the 5-ASA or sulphapyridine components is unknown. Several mechanisms of action have been proposed for 5-ASA and SASP including interference in the metabolism of arachidonic acid to prostaglandins and leukotrienes, scavenging,of reactive oxygen species, effects on leucocyte function and production of cytokines. However, it is unlikely that the anti-inflammatory properties of SASP and 5-ASA are due to several different properties but more likely that a single property of 5-ASA explains the theraapeutic effects of 5-ASA and SASP. Reactive oxygen species (ROS) are involved in the metabolism of prostaglandins and leukotrienes and can act as second messengers, and so the scavenging of ROS may be the single mechanism of action of 5-ASA that gives rise to its antiinflammatory effects in both inflammatory bowel disease and rheumatoid arthritis.
Introduction
Although corticosteroids are the major antiinflammatory agents used to treat the chronic inflammatory conditions rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), another useful agent is the salicylate derivative 5-aminosalicylic acid (5-ASA). 5 -ASA has been used for over half a century in the pro-drug form sulphasalazine (SASP) to treat ulcerative colitis (UC), but was originally designed for use in RA, in which, until relatively recently, it has not been widely used. More recently, SASP has also been used in the treatment of mild psoriasis.
In the late 1930s Dr Nanna Svartz of the Karolinska Institute, Stockholm, became interested in treating RA, believed then to be due to an infectious agent, with the recently developed anti-bacterial agents, the sulphonamides, which were beneficial in the treatment of septic arthritis. 2 However, treatment with these agents either alone or in conjunction with salicylates, which were already used to treat RA, proved ineffective. As salicylate drugs reduced the swelling in inflamed joints but had a lesser effect in reducing inflammation elsewhere in the body it was possible that they became concentrated in the joints, and thus Dr Svartz However, as a result of a chance meeting she convinced Pharmacia in Stockholm to help 2 and in collaboration with their chemists, E. Askelof and Dr P. H. Willstaedt, a variety of different combinations of salicylate and sulphonamide were produced. One of these, salicylazosulphapyridine, more commonly referred to as sulphasalazine (SASP) and consisting of 5-aminosalicylic acid (5-ASA) and sulphapyridine (SP) joined together by a diazo bond, proved to be effective in treating RA.
In collaboration with Sture Helander, SASP was shown to have an affinity for connective and elastic tissue, such as in the joint capsules and in the bowel, to the extent of forming deposits that gradually broke down to produce 5-ASA and SP. [3] [4] [5] As in UC the inflammatory changes occurred in the subepithelial connective tissue and as SP had been used with moderate success by Dr Svartz in the treatment of UC, which was then also believed to be due to an infectious agent, 6 ,v she treated UC patients with SASP and found that "some cases which did not become free of symptoms with sulphapyridine rapidly improved with salazopyrine". 6 However, the Second World War and the development of more effective gold based drugs in 9 and the UK, and in 1963 the first controlled, double-blind trials showed SASP to be effective in the treatment of mild UC, 1 and later in maintaining remission of UC. 1 In the 1970s its use for RA was rediscovered 2 and confirmed in a series of studies. 3 In 1977 direct application of the components of SASP to the colonic mucosa in patients with acute UC demonstrated that 5-ASA, but not SP, produced remission in UC similar to that achieved with SASP, TM as confirmed in other studies, 15'6 and that SP was relatively inactive. 17 Thus it is now considered that in the treatment of UC the SASP acts as a pro-drug, with SP acting as a carrier, delivering the active moiety, 5-ASA, to the inflamed colon. The (CD) .
In RA, although some studies have indicated that SP may be the active moiety [18] [19] [20] [21] due to a bacteriostatic effect, others show that SP on its own is ineffective 22 and it has been suggested that the intact SASP molecule may possess anti-inflammatory properties. [23] [24] [25] The ability of SASP to accumulate in connective tissues of the joints where it is broken down to release 5-ASA, raises the possibility that SASP may act also as a pro-drug in RA, but delivering 5-ASA, the active component, to the inflamed joint where it is slowly released. The lack of effect of oral 5 (NSAIDs) are considered to act through inhibition of the cyclooxygenase pathway, and so increased PG production by the inflamed bowel on removal of SASP treatment or decreased production with SASP 27'28'34'36 or 5-ASA 5' suggested that the mechanism of action of SASP and 5-ASA was also through inhibition of the cyclooxygenase enzyme.
Earlier in vitro studies supported this, but later ones do not (Tables 1 and 2 41 or by a dose related, but not significant, enhancement. 4 Although SP enhanced production of one out of four PGs measured in one study, 4 in the others, either in cell free incubations, 33'4'43'47'48 In these studies PGI 2 and TXA were measured as their respective stable hydrolysis products 6KFI and TXB2. no effect; enhancement;
inhibition. NA no effect on any PGs measured, as opposed to those PGs measured as stated which were effected.
# In this study the sum of both PGs was reported.
Enhancement in this study was not significant but as it is large and increased with increasing concentration of drug we have included it.
In this study results are presented as % inhibition and this enhancement is apparent as negative (<0%) inhibition which is reduced with increasing concentration to produce inhibition at high concentrations. d In this study whether PG production was enhanced or inhibited depended on the concentration of substrate used. In these studies PGI 2 and TXA2 were measured as their respective stable hydrolysis products 6KFI and TXB 2. no effect; 1' enhancement;
In this study results are presented as % inhibition and this enhancement is apparent as negative (<0%) inhibition which is reduced with increasing concentration to produce inhibition at high concentrations.
d In this study whether PG production was enhanced or inhibited depended on the concentration of substrate used.
All concentrations have been converted to mol I-1 to allow direct comparison.
with LPS. The increase in production of PG by MN cells from healthy subjects with 5-ASA 38's4 is much less than that found using MN cells from IBD patients. 46 
